Molecular pathophysiology of metabolic effects of antipsychotic medications

Trends in Endocrinology and Metabolism

Volumn 25, Issue 11, 2014, Pages 593-600

  Ballon, Jacob S ^a,b   Pajvani, Utpal ^a,c   Freyberg, Zachary ^a,b   Leibel, Rudolph L ^a,c   Lieberman, Jeffrey A ^a,b  

^a Columbia University ^*  (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^c Naomi Berrie Diabetes Center   (United States)

Author keywords

Antipsychotic drugs; Diabetes; Insulin resistance; Schizophrenia; Weight regulation

Indexed keywords

HISTAMINE; NEUROLEPTIC AGENT; NEUROTRANSMITTER RECEPTOR; SEROTONIN;

CALORIC INTAKE; DIABETES MELLITUS; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; METABOLIC DISORDER; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; WEIGHT GAIN; ANIMAL; BODY WEIGHT; CHEMICALLY INDUCED; DRUG EFFECTS; ENERGY METABOLISM; GENETICS; GLUCOSE INTOLERANCE; METABOLISM;

ANIMALS; ANTIPSYCHOTIC AGENTS; BODY WEIGHT; ENERGY INTAKE; ENERGY METABOLISM; GLUCOSE INTOLERANCE; HUMANS; METABOLIC DISEASES; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 84927625717     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2014.07.004     Document Type: Review

References (72)

1. Hennekens C.H., et al. Schizophrenia and increased risks of cardiovascular disease. Am. Heart J. 2005, 150:1115-1121.
2. Pachas G.N., et al. Varenicline for smoking cessation in schizophrenia: safety and effectiveness in a 12-week open-label trial. J. Dual Diagn. 2012, 8:117-125.
3. Lieberman J.A., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005, 353:1209-1223.
4. De Hert M., et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat. Rev. Endocrinol. 2012, 8:114-126.
5. Whiteley L., et al. Should diabetes be considered a coronary heart disease risk equivalent? Results from 25 years of follow-up in the Renfrew and Paisley Survey. Diabetes Care 2005, 28:1588-1593.
6. Vancampfort D., et al. A meta-analysis of cardio-metabolic abnormalities in drug naive, first-episode and multi-episode patients with schizophrenia versus general population controls. World Psychiatry 2013, 12:240-250.
7. Henneman D.H., et al. Carbohydrate metabolism in brain disease: Ii. glucose metabolism in schizophrenic, manic-depressive, and involutional psychoses. AMA Arch. Intern. Med. 1954, 94:402-416.
8. Kasanin J. The blood sugar curve in mental disease: Ii. the schizophrenic (dementia praecox) groups. Arch. Neurol. Psychiatry 1926, 16:414-419.
9. Fernandez-Egea E., et al. Metabolic profile of antipsychotic-naive individuals with non-affective psychosis. Br. J. Psychiatry 2009, 194:434-438.
10. Spelman L.M., et al. Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia. Diabet. Med. 2007, 24:481-485.
11. Mitchell A.J., et al. Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients. Schizophr. Bull. 2013, 39:295-305.
12. Greenwood T.A., et al. Association analysis of 94 candidate genes and schizophrenia-related endophenotypes. PLoS ONE 2012, 7:e29630.
13. Kvajo M., et al. A mutation in mouse Disc1 that models a schizophrenia risk allele leads to specific alterations in neuronal architecture and cognition. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:7076-7081.
14. Bernal-Mizrachi E., et al. Defective insulin secretion and increased susceptibility to experimental diabetes are induced by reduced Akt activity in pancreatic islet β cells. J. Clin. Invest. 2004, 114:928-936.
15. Emamian E.S., et al. Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat. Genet. 2004, 36:131-137.
16. Parsons B., et al. Weight effects associated with antipsychotics: a comprehensive database analysis. Schizophr. Res. 2009, 110:103-110.
17. Fountaine R.J., et al. Increased food intake and energy expenditure following administration of olanzapine to healthy men. Obesity 2010, 18:1646-1651.
18. Kluge M., et al. Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study. J. Clin. Psychopharmacol. 2007, 27:662-666.
19. Gothelf D., et al. Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia. J. Neural Transmission 2003, 110:545-560.
20. Roerig J.L., et al. A comparison of the effects of olanzapine and risperidone versus placebo on eating behaviors. J. Clin. Psychopharmacol. 2005, 25:413-418.
21. Gothelf D., et al. Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. Am. J. Psychiatry 2002, 159:1055-1057.
22. Rosenbaum M., et al. Energy intake in weight-reduced humans. Brain Res. 2010, 1350:95-102.
23. Leibel R.L., et al. Changes in energy expenditure resulting from altered body weight. N. Engl. J. Med. 1995, 332:621-628.
24. Pouzet B., et al. Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human. Pharmacol. Biochem. Behav. 2003, 75:133-140.
25. Coccurello R., et al. Chronic administration of olanzapine induces metabolic and food intake alterations: a mouse model of the atypical antipsychotic-associated adverse effects. Psychopharmacology 2006, 186:561-571.
26. Davoodi N., et al. Hyperphagia and increased meal size are responsible for weight gain in rats treated sub-chronically with olanzapine. Psychopharmacology 2009, 203:693-702.
27. Cooper G., et al. Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities. J. Psychopharmacol. 2007, 21:405-413.
28. Perry P.J., et al. Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial. J. Clin. Psychopharmacol. 2001, 21:14-20.
29. Cope M.B., et al. Antipsychotic drug-induced weight gain: development of an animal model. Int. J. Obes. (Lond.) 2005, 29:607-614.
30. Shobo M., et al. Two models for weight gain and hyperphagia as side effects of atypical antipsychotics in male rats: validation with olanzapine and ziprasidone. Behav. Brain Res. 2011, 216:561-568.
31. Chua S.C., et al. Food deprivation and hypothalamic neuropeptide gene expression: effects of strain background and the diabetes mutation. Brain Res. Mol. Brain Res. 1991, 11(3-4):291-299.
32. Ferno J., et al. Olanzapine-induced hyperphagia and weight gain associate with orexigenic hypothalamic neuropeptide signaling without concomitant AMPK phosphorylation. PLoS ONE 2011, 6:e20571.
33. Plum L., et al. Central insulin action in energy and glucose homeostasis. J. Clin. Invest. 2006, 116:1761-1766.
34. Lundy R.F. Gustatory hedonic value: potential function for forebrain control of brainstem taste processing. Neurosci. Biobehav. Rev. 2008, 32:1601-1606.
35. Tao Y.X. The melanocortin-4 receptor: physiology, pharmacology, and pathophysiology. Endocr. Rev. 2010, 31:506-543.
36. Malhotra A.K., et al. Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. Arch. Gen. Psychiatry 2012, 69:904-912.
37. Lett T.A., et al. Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. Mol. Psychiatry 2012, 17:242-266.
38. Ishizuka T., et al. A role of the histaminergic system for the control of feeding by orexigenic peptides. Physiol. Behav. 2006, 89:295-300.
39. Kim S.F., et al. From the cover: antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:3456-3459.
40. Minokoshi Y., et al. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature 2004, 428:569-574.
41. Dietrich M.O., Horvath T.L. Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons. Nat. Rev. Drug Discov. 2012, 11:675-691.
42. Nonogaki K., et al. Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene. Nat. Med. 1998, 4:1152-1156.
43. Kring S.I., et al. Polymorphisms of serotonin receptor 2A and 2C genes and COMT in relation to obesity and type 2 diabetes. PLoS ONE 2009, 4:e6696.
44. Manu P., et al. Insulin secretion in patients receiving clozapine, olanzapine, quetiapine and risperidone. Schizophr. Res. 2013, 143:358-362.
45. Albaugh V.L., et al. A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers. PLoS ONE 2011, 6:e22662.
46. Teff K.L., et al. Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease. Diabetes 2013, 62:3232-3240.
47. Martins P.J., et al. Central nervous system delivery of the antipsychotic olanzapine induces hepatic insulin resistance. Diabetes 2010, 59:2418-2425.
48. Zhang Q., et al. Hydrogen sulfide preconditioning protects rat liver against ischemia/reperfusion injury by activating Akt-GSK-3beta signaling and inhibiting mitochondrial permeability transition. PLoS ONE 2013, 8:e74422.
49. Anlauf M., et al. Expression of the two isoforms of the vesicular monoamine transporter (VMAT1 and VMAT2) in the endocrine pancreas and pancreatic endocrine tumors. J. Histochem. Cytochem. 2003, 51:1027-1040.
50. Simpson N., et al. Dopamine-mediated autocrine inhibitory circuit regulating human insulin secretion in vitro. Mol. Endocrinol. 2012, 26:1757-1772.
51. Holt R.I., et al. Bromocriptine: old drug, new formulation and new indication. Diabetes Obes. Metab. 2010, 12:1048-1057.
52. Holst J.J., et al. The incretin system and its role in type 2 diabetes mellitus. Mol. Cell. Endocrinol. 2009, 297:127-136.
53. Vidarsdottir S., et al. Short-term treatment with olanzapine does not modulate gut hormone secretion: olanzapine disintegrating versus standard tablets. Eur. J. Endocrinol. 2010, 162:75-83.
54. Van Der Zwaal E., et al. The acute effects of olanzapine on ghrelin secretion, CCK sensitivity, meal size, locomotor activity and body temperature. Int. J. Obes. (Lond.) 2012, 36:254-261.
55. Mason B., et al. The central nervous system sites mediating the orexigenic actions of ghrelin. Annu. Rev. Physiol. 2014, 76:519-533.
56. Pajvani U.B., Scherer P.E. Adiponectin: systemic contributor to insulin sensitivity. Curr. Diab. Rep. 2003, 3:207-213.
57. Pajvani U.B., et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J. Biol. Chem. 2004, 279:12152-12162.
58. Richards A.A., et al. Olanzapine treatment is associated with reduced high molecular weight adiponectin in serum: a potential mechanism for olanzapine-induced insulin resistance in patients with schizophrenia. J. Clin. Psychopharmacol. 2006, 26:232-237.
59. Oriot P., et al. Insulin sensitivity, adjusted beta-cell function and adiponectinaemia among lean drug-naive schizophrenic patients treated with atypical antipsychotic drugs: a nine-month prospective study. Diabetes Metab. 2008, 34:490-496.
60. Wampers M., et al. Differential effects of olanzapine and risperidone on plasma adiponectin levels over time: results from a 3-month prospective open-label study. Eur. Neuropsychopharmacol. 2012, 22:17-26.
61. Sugai T., et al. Dysregulation of adipocytokines related to second-generation antipsychotics in normal fasting glucose patients with schizophrenia. J. Clin. Psychopharmacol. 2012, 32:390-393.
62. Pocai A., et al. A brain-liver circuit regulates glucose homeostasis. Cell Metab. 2005, 1:53-61.
63. Gelling R.W., et al. Insulin action in the brain contributes to glucose lowering during insulin treatment of diabetes. Cell Metab. 2006, 3:67-73.
64. Gershon M.D. 5-Hydroxytryptamine (serotonin) in the gastrointestinal tract. Curr. Opin. Endocrinol. Diabetes Obes. 2013, 20:14-21.
65. Elmquist J.K., et al. Identifying hypothalamic pathways controlling food intake, body weight, and glucose homeostasis. J. Comp. Neurol. 2005, 493:63-71.
66. Girgis R.R., et al. Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway. Mol. Psychiatry 2008, 13:918-929.
67. Miyamoto S., et al. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol. Psychiatry 2012, 17:1206-1227.
68. Zhang J-P., et al. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int. J. Neuropsychopharmacol. 2013, 16:1205-1218.
69. Arana G.W. An overview of side effects caused by typical antipsychotics. J. Clin. Psychiatry 2000, 61(Suppl. 8):5-13.
70. Gordon H., et al. The problem of overweight in hospitalized psychotic patients. Psychiatr. Q. 1960, 34:69-82.
71. Allison D.B., et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry 1999, 156:1686-1696.
72. Kendall T. The rise and fall of the atypical antipsychotics. Br. J. Psychiatry 2011, 199:266-268.